HALIFAX, Dec. 2, 2013 /CNW/ - MedMira, Inc. (MedMira) (TSXV: MIR), a developer of rapid diagnostic technology and solutions, today announced that Dan Frid, the Company's Chief Financial Officer, will leave the Company effective December 6, 2013, to pursue other professional opportunities. Frid has served as MedMira's CFO since July 2010, with overall responsibility for financial and accounting operations, strategic fiscal planning, accountability and analysis, and contributed to various corporate support and administrative functions.
"We would like to thank Dan for his leadership and contributions to the Company," said Hermes Chan, Chief Executive Officer of MedMira Inc. "Dan has been committed to this organization and has added to the strength of its financial position. We wish him all the best in his future endeavours."
The Company has identified a new CFO and a detailed announcement will be issued shortly.
MedMira is the leading developer and manufacturer of flow-through rapid diagnostics and technologies. MedMira is the only Canadian company to be awarded US Army contracts for the development of rapid tests for HIV and Hepatitis viruses. The Company's testing solutions provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The Company's tests are sold under the Reveal®, Multiplo™ and Miriad brands in global markets. MedMira is located in Halifax, Nova Scotia, Canada. www.medmira.com.
This news release contains forward-looking statements, including statements relating to growth in the Company's business, earnings and profitability, and trends in demand for the Company's products, which involve risk and uncertainties and reflect the Company's current expectation regarding future events including statements regarding possible future growth and new business opportunities. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: MEDMIRA INC.
For further information:
Andrea Young, Corporate Communications
Email: [email protected]